KB109 + Self Supportive Care (SSC)

OTHER2 trials

Sponsors

Kaleido Biosciences

Conditions

Mild-to-Moderate COVID-19Mild-to-moderate COVID-19

Unknown Phase

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

CompletedNCT04414124

Kaleido BiosciencesMild-to-moderate COVID-19

Start: 2020-08-02End: 2021-02-02Updated: 2021-08-13

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

CompletedNCT04486482

Kaleido BiosciencesMild-to-Moderate COVID-19

Start: 2021-01-12End: 2021-03-30Updated: 2021-08-13

Related Papers

Lost microbes of COVID-19: <i>Bifidobacterium</i> , <i>Faecalibacterium</i> depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity

BMJ Open Gastroenterology2022-04-0184 citations

Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.

2021-04-027 citations